Expression of AR, 5αR1 and 5αR2 in Bladder Urothelial Carcinoma and Relationship to Clinicopathological Factors

    September 2017 in “ Life sciences
    Shuko Hata, Kazue Ise, Abdullah Azmahani, Sachiko Konosu-Fukaya, Keely May McNamara, Fumiyoshi Fujishima, Kaoru Shimada, Koji Mitsuzuka, Yoichi Arai, Hironobu Sasano, Yasuhiro Nakamura
    TLDR Androgens may influence bladder cancer progression by affecting cellular behavior.
    The study investigated the expression of androgen receptor (AR) and androgen-producing enzymes 5α-reductase type 1 (5αR1) and type 2 (5αR2) in bladder urothelial carcinoma and their relationship to clinicopathological factors. It was found that AR, 5αR1, and 5αR2 immunoreactivity decreased with increasing carcinoma grade. In vitro experiments using the T24 bladder carcinoma cell line showed that treatment with the androgen agonist 5α-dihydrotestosterone (DHT) significantly increased AR expression and cell proliferation, but did not affect 5αR1 or 5αR2 expression. This suggests that AR may play a role in bladder cancer progression, potentially explaining the higher incidence in men.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    6 / 1000+ results